Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PPOX | P50336 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10582955 | 0.75 | PARP1 (0.37) | PARP1PPOXGSK3BMAOAMAOB | |
| SCHEMBL709378 | 0.75 | GSK3B (0.43) | PARP1GSK3B | |
| SCHEMBL10911536 | 0.70 | GSK3B (0.41) | PARP1PPOXGSK3BCHEK1WEE1 | |
| SCHEMBL10986100 | 0.66 | GSK3B (0.38) | PARP1PPOXGSK3BCHEK1WEE1 | |
| SCHEMBL6929455 | 0.66 | WEE1 (0.37) | PARP1PPOXGSK3BCHEK1WEE1 | |
| SCHEMBL11615863 | 0.65 | SRD5A1 (0.44) | PARP1PPOXCHEK1WEE1 | |
| SCHEMBL28597691 | 0.65 | ELANE (0.40) | PARP1GSK3BCHEK1 | |
| SCHEMBL2312949 | 0.65 | PARP1 (0.39) | PARP1PPOXGSK3BMAOAMAOB | |
| SCHEMBL4975643 | 0.65 | PARP1 (0.39) | PARP1PPOXGSK3BMAOAMAOB | |
| SCHEMBL31195685 | 0.64 | PARP1 (0.35) | PARP1PPOXGSK3BMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518450-B2 | Adrenergic blocking agent | NATIONAL SCIENCE COUNCIL (TW) | 2003-02-11 | — | — | US | disclosed |
| US-20010056211-A1 | Guaiacoxypropanolamines with alpha/beta adrenergic blocking activity | NATIONAL SCIENCE COUNCIL (TW) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056211-A1 | Guaiacoxypropanolamines with alpha/beta adrenergic blocking activity | ADRB1, ADRA1A, ADRA1B | PARP1 3080/4885PPOX 2483/4885GSK3B 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.